Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Russell NH, Thomas A, Hills RK, Thomas I, Gilkes A, Almuina NM, Burns S, Marsh L, Vyas P, Metzner M, McCarthy N, Andrew G, Byrne J, Sellar RS, Kelly R, Cahalin P, Overgaard UM, Mehta P, Dennis M, Knapper S, Freeman SD.
Russell NH, et al. Among authors: burns s.
J Clin Oncol. 2024 Nov 18:JCO2400259. doi: 10.1200/JCO.24.00259. Online ahead of print.
J Clin Oncol. 2024.
PMID: 39556780